+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neurotransmitter"

Dementia with Diabetes - Pipeline Insight, 2024 - Product Thumbnail Image

Dementia with Diabetes - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Spasmodic-torticollis - Pipeline Insight, 2024 - Product Thumbnail Image

Spasmodic-torticollis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Refractory status epilepticus - Pipeline Insight, 2024 - Product Thumbnail Image

Refractory status epilepticus - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Vascular Dementia - Pipeline Insight, 2024 - Product Thumbnail Image

Vascular Dementia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
From
Epilepsy - Epidemiology Forecast - 2032 - Product Thumbnail Image

Epilepsy - Epidemiology Forecast - 2032

  • Report
  • January 2024
  • 197 Pages
  • Global
From
Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 100 Pages
  • Global
From
Dopamine D1 receptor antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Dopamine D1 receptor antagonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Cannabinoid receptor CB1 inverse agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Cannabinoid receptor CB1 inverse agonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Alpha-synuclein inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Alpha-synuclein inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
GABA A receptor agonist - Pipeline Insight, 2024 - Product Thumbnail Image

GABA A receptor agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Dopamine D2 receptor antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Dopamine D2 receptor antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Glutamate Receptor Antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Glutamate Receptor Antagonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
From
Sleep Disorders Treatment: Global Market Outlook - Product Thumbnail Image

Sleep Disorders Treatment: Global Market Outlook

  • Report
  • March 2023
  • 57 Pages
  • Global
From
From
United States AUSTEDO Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

United States AUSTEDO Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • United States
From
Ingrezza Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Ingrezza Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
From
Loading Indicator

The Neurotransmitter market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Neurotransmitters are chemicals that are released by neurons to send signals to other cells. These drugs are used to treat a variety of neurological disorders, including depression, anxiety, and schizophrenia. Neurotransmitter drugs work by either increasing or decreasing the amount of neurotransmitters in the brain. The Neurotransmitter market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, GlaxoSmithKline, Eli Lilly, and Merck. Other companies such as Novartis, AstraZeneca, and Johnson & Johnson also have a presence in the Neurotransmitter market. Show Less Read more